Tele: 561.316.3330
Breaking Medical Device News

Wednesday, October 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

November 13, 2019: ELT Sight, Inc. today announced the company has acquired the IP and assets of MLase AG’s excimer ophthalmic laser system for glaucoma surgery. MLase manufactures and markets innovative laser systems, including the ExTra ELT Laser and disposable applicator used to perform implant-free micro-invasive glaucoma surgery. The system received European Conformity (CE) certification in 2014 and is currently available in Europe. ELT Sight plans to expand marketing activities in Europe and initiate clinical studies in the United States in early 2020. The terms for the acquisition were not disclosed.

Glaucoma is the third leading cause of blindness worldwide, and the number of affected individuals is growing as the population ages. Current treatment options, including daily eye drops and invasive shunts and stents, are suboptimal for patients and providers. Excimer Laser Trabeculostomy (ELT) is a completely implant-free micro-invasive glaucoma surgery that was first used clinically in Europe in 1997. This outpatient procedure has shown superior results and a favorable safety profile in European studies with sustained, multi-year reduced intraocular pressure (IOP) and decreased medication use.

“There is a growing need for new solutions to address glaucoma, a global health challenge expected to affect 80 million people worldwide in 2020. Clinical studies in Europe have demonstrated that the ExTra ELT Laser system offers patients with glaucoma an implant-free choice to lower eye pressure,” said Elliott Friedman, Chief Executive Officer of ELT Sight. “Our hope is to simultaneously ramp up marketing activities in Europe while conducting clinical trials in the United States early next year.”

The ExTra ELT Laser and disposable applicator will continue to be manufactured by MLase in Germany. ELT treats the pathology leading to open-angle glaucoma exactly where it occurs by increasing the permeability of the trabecular meshwork, with studies showing lower risks than other treatment methods. The outpatient procedure is completed in less than 10 minutes.

“MLase has an excellent reputation for developing and manufacturing innovative laser systems, and we look forward to collaborating with them as we focus on making this system available to the millions of patients affected by glaucoma worldwide,” Mr. Friedman added.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

By using this website you agree to accept Medical Device News Magazine Privacy Policy